RPCEC00000183
Completed
未知
Study of intensive pediatric pharmacovigilance of monoclonal antibody nimotuzumab for the treatment of malignant glioma tumors
Centro de Inmunología Molecular (CIM)0 sites160 target enrollmentAugust 14, 2014
ConditionsMalignant gliomas
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Malignant gliomas
- Sponsor
- Centro de Inmunología Molecular (CIM)
- Enrollment
- 160
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Children and adolescents between 2 and 19 years of age of btoh gender (male and female)
- •2\. Diagnoses by histology/pathology documented or by images if stem tumor.
- •3\. Life expectancy of at least 4 weeks.
- •4\. Karnofsky / Lansky \= 50%.
Exclusion Criteria
- •1\. Participation in another trial.
- •2\. Pregnant or breastfeeding.
- •3\. Decompensated chronic disease.
- •4\. Acute septic processes.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Multicentre trial in to investigate the usage of antidepressant and antipsychotics (with / without approval) in patients at the age of children and adolescentstherapeutic use in clinical practiseTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2013-004881-33-DEniversitätsklinikum Würzburg710
Active, not recruiting
Phase 1
Multicentre trial in to investigate the usage of antidepressant and antipsychotics (with / without approval) in patients at the age of children and adolescentsEUCTR2013-004881-33-ATKompetenznetz TDM-KJP e.V.1,000
Active, not recruiting
Phase 1
A PAEDIATRIC PHASE I/II STUDY OF INTERMITTENT DOSING OF THE MEK-1 INHIBITOR SELUMETINIB IN CHILDREN WITH NEUROFIBROMATOSIS TYPE-1 AND INOPERABLE PLEXIFORM NEUROFIBROMA AND/OR PROGRESSIVE OPTIC PATHWAY GLIOMANeurofibromatosis type 1 associated plexiform neurofibromas Neurofibromatosis type 1 associated progressive or relapsed optic pathway gliomaMedDRA version: 20.0 Level: LLT Classification code 10029270 Term: Neurofibromatosis, type 1 (von Recklinghausen's disease) System Organ Class: 100000004850MedDRA version: 20.0 Level: LLT Classification code 10065866 Term: Plexiform neurofibroma System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10030935 Term: Optic nerve glioma System Organ Class: 100000004864Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2017-002635-41-GBGreat Ormond Street Hospital38
Recruiting
Not Applicable
Pediatric Alarm Study For Physiologic Monitoring in General WardJPRN-UMIN000033727Department of General Pediatrics, Tokyo Metropolitan Children's Medical Center400
Recruiting
Not Applicable
A prospective observational study in child patients with RSV infectioRSV infectionJPRN-jRCT1030230252Ishiwada Naruhiko100